Joris Silon

Patients

In November, NICE backed NHS use of AstraZeneca’s diabetes and heart failure drug Forxiga for the treatment of chronic kidney disease.

Views & Analysis

AstraZeneca is hoping to build a strong focus on cardiovascular, renal, and metabolic (CVRM) diseases.

News

The rivalry between Novo Nordisk and Eli Lilly in the GLP-1 market has spilled over into the courts in the US, with claims of misleading advertising.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.